Complete Omics Inc. Founder Qing Wang Featured on Wharton Business School’s Official Website
July 27, 2023 | BALTIMORE – Complete Omics is proud to announce a momentous occasion for Complete Omics Inc.: our visionary founder, Qing Wang, has been featured on the prestigious Wharton Business School’s official website in a piece that celebrates and explores the journey of empowering entrepreneurs.
Thrilled to Welcome Dr. Raghothama Chaerkady as the Leader of Our Clinical Proteomics Team
July 15, 2023 | BALTIMORE – Complete Omics team are excited to announce that Dr. Raghothama Chaerkady, a globally recognized proteomics expert, has joined us as the leader of our clinical proteomics team, MyProt Force. Dr. Chaerkady’s journey in proteomics is marked by his instrumental role in publishing the milestone paper, “A Draft Map of the Human Proteome,” in Nature in 2014—a work that has significantly advanced the field of proteomics, particularly in biomarker discovery.
Exciting News from the MyMeta Force Team!
June 1, 2023 | BALTIMORE – Complete Omics’ Clinical Metablomics team are overjoyed to announce that Dr. Liang Zhao, an esteemed expert in metabolomics, proteomics, and lipidomics, with a profound focus on cancer metabolism and immuno-metabolism, has joined our MyMeta Force team as the leader. Dr. Zhao’s pioneering research involves the sophisticated application of mass spectrometry-based metabolomics and proteomics, alongside integrating molecular biology and bioinformatics, to unravel the biomedical significance of metabolites and proteins. His dedication to translating omics findings into clinical applications is notable, aiming at the development of innovative biomarkers, AI-enhanced diagnostic panels, and novel therapeutic strategies for cancer treatment.
Exciting Feature: Complete Omics and Our Founder Qing Wang Shine on The Scientist’s Channel!
July 18, 2021 | BALTIMORE – Complete Omics team is thrilled to announce an extraordinary milestone for Complete Omics Inc. The Scientist’s Channel, renowned for spotlighting the trailblazers at the forefront of scientific inquiry and innovation, has featured our esteemed founder, Qing Wang, in a compelling showcase that highlights the groundbreaking work we are doing here at Complete Omics.
Detecting and Absolutely Quantifying Patient-specific Neoantigens from Limited Input of Biopsy Sample — An Integrated Pipeline for Neoantigen-targeted Cancer Treatments
Neoantigens derived from HERVs represent a new group of cancer therapeutic targets. In a collaborating project, Complete Omics identified and quantified HERVs derived neoantigens and provided solid evidence for developing targeted therapies.
Identifying and Quantifying Neoantigens derived from Human endogenous retroviruses (HERVs) — A new class of targets to expand the benefits of cancer immunotherapy.
Neoantigens derived from HERVs represent a new group of cancer therapeutic targets. In a collaborating project, Complete Omics identified and quantified HERVs derived neoantigens and provided solid evidence for developing targeted therapies.
